Gilead CEO scores $187 million in 2014 gains

March 27, 2015 7:19 PM

16 0

Gilead Sciences CEO John Martin has long been among Corporate America's best-compensated executives. But the biotech king scored one of his best years ever in 2014.

Gilead — whose hepatitis C treatment, Sovaldi, can cost patients up to $84,000 for a 12-week treatment — said Martin received compensation valued at $18.9 million last year and gained $187.4 million from previously awarded stock options and restricted shares.

Also read: PayPal Agrees to Buy Payments Firm Hyperwallet for $400 Million

Read more

To category page